AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3003317
Drug: Citrate-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-containing oral rehydration solution
Trial: 28367952
Drug: B-vitamin supplementation
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin supplementation (2.5 mg/d folic acid, 50 mg/d vitamin B6, 1 mg/d vitamin B12)
Trial: 9754894
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (enoxaparin) with or without TED stockings
Trial: 8132702
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg coumarin and cimetidine daily
Trial: 8132702
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g coumarin daily
Trial: 8132702
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g coumarin daily
Trial: 3043033
Drug: Cefbuperazone (CBPZ)
RxNorm normalized name: cefbuperazone
DrugBank: Cefbuperazone (DB13638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefbuperazone (CBPZ) 4 g/day
Trial: 3043033
Drug: Cefbuperazone (CBPZ)
RxNorm normalized name: cefbuperazone
DrugBank: Cefbuperazone (DB13638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefbuperazone (CBPZ) 2 g/day
Trial: 1473409
Drug: Oral gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gentamicin and metronidazole for two days
Trial: 1473409
Drug: Combined (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (oral + i.v.) gentamicin and metronidazole
Trial: 26047892
Drug: Esmirtazapine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmirtazapine (both doses)
Trial: 21451509
Drug: CCX354 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX354 100 mg single dose
Trial: 21451509
Drug: CCX354 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX354 300 mg single dose
Trial: 21451509
Drug: CCX354 1-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX354 1-300 mg/day oral doses
Trial: 16622646
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (600 mg/day during chemotherapy and 3 months after cessation)
Trial: 15228804
Drug: robot training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: robot training plus conventional therapy
Trial: 2927483
Drug: Trimethoprim-sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160 mg and 800 mg, given orally four times a day for 10 days, then 160 mg and 800 mg three times a week)
Trial: 2927483
Drug: Sulfadoxine and
RxNorm normalized name: Sulfadoxine and Pyrimethamine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine and pyrimethamine (500 mg and 25 mg weekly)
Trial: 24689695
Drug: Nurse-guided, basal-prandial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-guided, basal-prandial insulin treatment protocol (NGP)
Trial: 24689695
Drug: Physician-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-guided therapy (PGT)
Trial: 21401358
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 18 months
Trial: 16571155
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of trans-11-18:1 (tVA) and 3 g/d of trans-12-18:1 (t12)
Trial: 12846896
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (r‐EPO) at a single, weekly dose of 40,000 U for at least 8 weeks
Trial: 7528126
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs in add-on trials
Trial: 7528126
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs in monotherapy designs
Trial: 30702538
Drug: Individualized opioid
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized opioid dosing protocol for VOE management
Trial: 30702538
Drug: Weight-based opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based opioid dosing protocol for VOE management
Trial: 25692556
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm long implants (test group)
Trial: 25692556
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm long implants (control group)
Trial: 25692556
Drug: Both 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 6 mm and 10 mm implants
Trial: 22343119
Drug: Immediate-postoperative isophane
RxNorm normalized name: insulin isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl
Trial: 22343119
Drug: Standard-of-care control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care control group (short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl)
Trial: 17503748
Drug: AI system
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI system for estimating drug exposure and interpreting pharmacokinetic data for LPV
Trial: 17503748
Drug: AI system
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI system for estimating drug exposure and interpreting pharmacokinetic data for EFV
Trial: 11592603
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (9 million units three times per week) and lamivudine (100 mg/daily) for 24 weeks
Trial: 11592603
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg/daily) for 52 weeks
Trial: 11592603
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b and lamivudine combination therapy
Trial: 9538976
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (LP) and Human regular insulin (HR)
Trial: 2116086
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium (0.6 mg/kg per day in four intravenous doses)
Trial: 30578048
Drug: RECELL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECELL treatment (combined with widely meshed STSG)
Trial: 30578048
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (standard meshed STSG)
Trial: 30578048
Drug: RECELL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECELL treatment
Trial: 30578048
Drug: RECELL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECELL treatment and Control treatment
Trial: 23981511
Drug: Minocycline (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (25-100 mg daily based on weight)
Trial: 20137620
Drug: Zenapax (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zenapax (induction therapy)
Trial: 20137620
Drug: Regular immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular immunosuppressive therapy (control group)
Trial: 15012174
Drug: Oral cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporin (CsA) with mycophenolate mofetil (2g daily) and prednisone (0.5-1 mg/kg daily)
Trial: 11404230
Drug: Gaboxadol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol (15 mg)
Trial: 9331118
Drug: Neoadjuvant paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant paclitaxel (200 mg/m2/3 hour, day 1) and carboplatin (AUC 5, day 2)
Trial: 2010565
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (8 g for 21 days)
Trial: 2010565
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (identical-looking capsules for 21 days)
Trial: 27729164
Drug: Preemptive intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive intra-articular 20 mL of bupivacaine 0.5% injection
Trial: 27729164
Drug: Preemptive periacetabular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive periacetabular 20 mL of bupivacaine 0.5% injection
Trial: 27729164
Drug: Total analgesic
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total analgesic consumption
Trial: 12870691
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of antituberculosis chemotherapy
Trial: 9175240
Drug: Pectin supplement
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin supplement (15 g/day)
Trial: 4002804
Drug: Muzolimine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muzolimine (20 mg per day)
Trial: 29609926
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Group (LDG): Two 90-min yoga classes plus three 30-min homework sessions weekly for 12 weeks.
Trial: 29609926
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Group (HDG): Three 90-min yoga classes plus four 30-min homework sessions weekly for 12 weeks.
Trial: 15101859
Drug: Morphine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (50 micro g kg(‐1) loading dose, followed by intravenous morphine-PCA)
Trial: 15101859
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (1 mg of morphine)
Trial: 2882060
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for 4 weeks)
Trial: 29548304
Drug: Coordinated medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordinated medication management model (CoMM) involving practical nurses and clinical pharmacists
Trial: 29548304
Drug: Community pharmacists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacists conducting medication reviews
Trial: 29548304
Drug: Implementation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation and follow-up of medication changes
Trial: 28473063
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein (HP) diet (1.5 g•kg‐1•d‐1 protein)
Trial: 28473063
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (0.8 g•kg‐1•d‐1 protein)
Trial: 23340711
Drug: Web-based psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychosocial treatment
Trial: 16481707
Drug: 1% lindane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lindane cream
Trial: 12582352
Drug: Single-dose clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose clindamycin (600 mg)
Trial: 12582352
Drug: 24-hour clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour clindamycin prophylaxis (600 mg total)
Trial: 9337609
Drug: Typical daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical daily dose of caffeine (400-1000 mg)
Trial: 9337609
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of caffeine in excess of daily consumption
Trial: 7903212
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tertatolol (T) once daily
Trial: 29860937
Drug: Sunitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib alone (50 mg daily in cycles of 28 days on and 14 days off)
Trial: 29860937
Drug: Nephrectomy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nephrectomy followed by sunitinib (50 mg daily in cycles of 28 days on and 14 days off)
Trial: 21953134
Drug: Routine occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine occupational therapy
Trial: 21356050
Drug: Open reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open reduction and internal fixation (surgical treatment using the Acumed clavicle fixation system)
Trial: 11794698
Drug: Clustered dosage
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clustered dosage (5 consecutive daily infusions at 5-week intervals)
Trial: 11794698
Drug: Nonclustered dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonclustered dosage (1 infusion weekly)
Trial: 24401214
Drug: Intensive rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive rosuvastatin therapy (achieve 30% lower LDL-C levels than standard)
Trial: 24401214
Drug: Standard rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rosuvastatin therapy (achieve LDL-C levels recommended by Japanese guidelines)
Trial: 23521655
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg.kg(‐1)) and propofol infusion (1.0 μg.ml(‐1) effect-site concentration)
Trial: 23521655
Drug: Flumazenil administration
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil administration
Trial: 21177169
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg) every night for 3 months in HLT and NLT groups
Trial: 14576764
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (exact dosage not specified)
Trial: 10553392
Drug: 22-mg, 24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg, 24-hour nicotine patch therapy (active patch)
Trial: 10553392
Drug: 22-mg, 24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-mg, 24-hour nicotine patch therapy (open label-pay)
Trial: 6683539
Drug: Tablet (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (100 mg)
Trial: 6683539
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (100 mg)
Trial: 6683539
Drug: Tablets (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (150 mg, 300 mg, 600 mg)
Trial: 31771448
Drug: Structured pre-simulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pre-simulation preparation and briefing (35 minutes)
Trial: 31771448
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation and briefing
Trial: 24246768
Drug: Probiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (1 × 10(8) colony‐forming units, 3 times daily; n = 86)
Trial: 22561055
Drug: Oral viscous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral viscous budesonide (OVB) 1 mg twice daily for 8 weeks
Trial: 22561055
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (NEB) 1 mg twice daily for 8 weeks
Trial: 18632181
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (33.3 mg/m² on days 1, 8, 15 q 4 weeks)
Trial: 18632181
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (30 mg/m² on days 1, 8, 15) plus gemcitabine (800 mg/m² on days 1, 8 q 4 weeks) or plus vinorelbine (20 mg/m² on days 1, 8 q 4 weeks)
Trial: 18632181
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (as in arm B) plus capecitabine (625 mg/m² twice daily on days 5-18 q 4 weeks)
Trial: 16907846
Drug: No antepartum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antepartum treatment
Trial: 14691614
Drug: Carbamazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (600 mg daily except 200 mg daily for the first 2 days)
Trial: 11297908
Drug: Scopolamine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine nasal spray (0.2%)
Trial: 9550476
Drug: Iloprost (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (50 microg orally twice daily)
Trial: 3076492
Drug: Dydrogesterone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (10 mg b.d.)
Trial: 23497020
Drug: Fermented turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented turmeric powder (FTP) 3.0 g per day for 12 weeks
Trial: 23497020
Drug: Placebo 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3.0 g per day for 12 weeks
Trial: 17875549
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of omega-3-polyunsaturated fatty acids
Trial: 9824785
Drug: K4MgCit2 (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K4MgCit2 (49 mEq K, 25 mEq Mg, and 74 mEq citrate/day)
Trial: 9824785
Drug: K3MgHCit2 (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K3MgHCit2 (49 mEq K, 33 mEq Mg, and 98 mEq citrate/day)
Trial: 9824785
Drug: K5MgCit2Cl (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K5MgCit2Cl (49 mEq K, 20 mEq Mg, 10 mEq Cl and 59 mEq citrate/day)
Trial: 7661060
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (53% of patients treated with a thrombolytic agent in 1992)
Trial: 7661060
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (no thrombolytic therapy in 1966 and 1981-1983)
Trial: 6815
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of ipecac orally
Trial: 6815
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg apomorphine subcutaneously
Trial: 25632066
Drug: C‐GEMOX (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐GEMOX (500 mg/m² cetuximab plus GEMOX: 800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Trial: 25632066
Drug: GEMOX (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX (800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Trial: 21613792
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment without inhibitors of the renin-angiotensin-aldosterone system (n = 21)
Trial: 16953530
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (morphine 5 mg at time zero and 5 mg at 20 minutes, ketorolac 15 mg at time zero and 15 mg at 20 minutes)
Trial: 16953530
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (5 mg at time zero and 5 mg at 20 minutes)
Trial: 16953530
Drug: Ketorolac alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac alone (15 mg at time zero and 15 mg at 20 minutes)
Trial: 14764773
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg alendronate daily for 2 years
Trial: 14764773
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol plus 1 mg norethisterone acetate daily for 2 years (HRT)
Trial: 14764773
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alendronate and HRT for 2 years
Trial: 11590393
Drug: Wheat ω-5
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat ω-5 gliadin IgE antibody testing
Trial: 11590393
Drug: Oral wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral wheat challenge
Trial: 3312625
Drug: 9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/kg methylprednisolone (steroid-treated)
Trial: 31547713
Drug: Conventional immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunotherapy in children
Trial: 31547713
Drug: Cluster immunotherapy
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster immunotherapy in children
Trial: 31547713
Drug: Conventional immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunotherapy in adults